Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 13/20 | 0.56 |
| ▸ | PARP1 | P09874 | 3/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16578729 | 0.87 | TLR9 (0.46) | TNKSPARP1TLR9TLR8TLR7 | |
| SCHEMBL16625167 | 0.86 | TNKS (0.73) | TNKSPARP1 | |
| SCHEMBL16625171 | 0.81 | TNKS (0.66) | TNKSPARP1 | |
| SCHEMBL16625169 | 0.81 | TNKS (0.57) | TNKSPARP1 | |
| SCHEMBL16625239 | 0.78 | TNKS (0.53) | TNKSPARP1 | |
| SCHEMBL16625170 | 0.78 | TNKS (0.68) | TNKSPARP1TLR9TLR8TLR7 | |
| SCHEMBL16625240 | 0.76 | TNKS (0.61) | TNKSPARP1TLR9TLR8TLR7 | |
| SCHEMBL16625193 | 0.76 | TNKS (0.67) | TNKSPARP1DRD2DRD3 | |
| SCHEMBL16616937 | 0.76 | TNKS (0.58) | TNKSPARP1TLR9TLR8TLR7 | |
| SCHEMBL16616653 | 0.75 | TNKS (0.77) | TNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | TNKS 1/4885PARP1 4/4885TLR9 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.